Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients-Reference-Cited by-同舟云学术

Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients

Published:2013-10-05 Issue:6 Volume:91 Page:522-533
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Elalfy Mohsen S.¹,Adly Amira A. M.¹,Ismail Eman A.²,Elhenawy Yasmine I.¹,Elghamry Islam R.¹

Affiliation:

1. Pediatrics Department; Faculty of Medicine; Ain Shams University; Cairo Egypt

2. Clinical Pathology Department; Faculty of Medicine; Ain Shams University; Cairo Egypt

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12182/fullpdf

Reference45 articles.

1. Erythropoietin;Krantz;Blood,1991

2. Erythropoietin: structure, control of production, and function;Jelkmann;Physiol Rev,1992

3. New insights into erythropoiesis;Koury;Curr Opin Hematol,2002

4. Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules;Chaidos;Acta Haematol,2004

5. Thalassemia intermedia: revisited;Taher;Blood Cells Mol Dis,2006

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias;Cochrane Database of Systematic Reviews;2023-01-13

2. Non-Transfusion-Dependent Thalassemia: A Panoramic Review;Medicina;2022-10-21

3. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial;The Lancet Haematology;2022-10

4. Thalassaemia;The Lancet;2022-06

5. The expression of BCL11A, KLF1, and ERK of mitogen-activated protein kinase pathway on stem cell factor and erythropoietin-treated K562 cells;Biomedical and Biotechnology Research Journal (BBRJ);2022